Related Experiment Video
Updated: Jun 4, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches: JACC: Heart Failure Position
Shannon M Dunlay1, Monica Colvin2, Jennifer A Cowger3
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Insights
New heart failure (HF) stage C2D recognizes ambulatory patients progressing beyond guideline-directed medical therapy (GDMT). This stage requires better understanding and tailored strategies to improve quality of life and extend meaningful years for advanced HF patients.
Area of Science:
- Cardiology
- Heart Failure Research
- Clinical Practice Guidelines
Background:
- Traditional heart failure (HF) staging categorizes patients into Stage C (manageable symptoms with guideline-directed medical therapy - GDMT) and Stage D (transplant, circulatory support, or palliation).
- Advanced HF encompasses not only end-stage patients but also a significant ambulatory population experiencing progression despite GDMT.
Purpose of the Study:
- To enhance recognition of a new HF stage, termed C2D, for ambulatory patients progressing beyond GDMT.
- To survey existing knowledge gaps regarding the extension of Stage C HF GDMT into the C2D stage.
- To propose future research directions for managing advanced HF.
Main Methods:
- This is a position statement commissioned to address advanced HF.
- Proposed next steps include identification and curation of C2D cohorts.
- Future research will involve dissecting physiological phenotypes, considering social determinants and patient preferences.
Main Results:
- Current HF staging may not fully capture the needs of ambulatory patients progressing on GDMT.
- There is a need to define therapeutic strategies for patients in the C2D stage.
- Understanding C2D patient phenotypes and preferences is crucial for developing new management approaches.
Conclusions:
- Recognizing and defining Stage C2D is essential for improving care in advanced heart failure.
- Further research into C2D cohorts, phenotypes, and patient-centered factors is needed.
- Developing novel strategies for the C2D stage can potentially alter HF trajectories and improve patient outcomes.
Abstract:
Symptomatic heart failure (HF) with reduced ejection fraction is traditionally drawn as 2 stages. Most stage C patients report manageable symptoms on guideline-directed medical therapy (GDMT), whereas stage D therapies are transplant or durable circulatory support, if eligible, and otherwise palliation with inotropic infusions or hospice considered for most. However, advanced HF includes not only end-stage D patients but also a large ambulatory population progressing beyond sustained response to GDMT who still seek and may find meaningful life-years ahead. This position statement was commissioned to enhance recognition of stage C2D, survey knowledge gaps for how stage C HF GDMT therapies should extend into C2D, and propose next steps. These include identification and curation of C2D cohorts and dissection of physiological phenotypes with social determinants and patient preferences as modifiers. Future focus on C2D will inform and inspire new strategies to revise trajectories beyond stage C2D and potentially throughout the HF journey.
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Pathophysiology of Heart Failure
